ASH 2014 – CLL

The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p

ASH 2014 – CLL

Safety Overview of the CLLM1 Trial: Lenalidomide Maintenance Therapy After Frontline Chemoimmunotherapy in High-Risk CLL

ASH 2014 – CLL

ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL

ASH 2014 – CLL

Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities

ASH 2014 – CLL

Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability

ASH 2014 – CLL

Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL

ASH 2014 – CLL

The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL

ASH 2014 – CLL

Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL

ASH 2014 – CLL

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 – CLL

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 – CLL

Page 2 of 3

1
2
3